Company performance
Add to research
Current Price
as of Feb 14, 2025$13.91
P/E Ratio
N/A
Market Cap
$1.42B
Description
Add to research
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Metrics
Add to research
Overview
- HQWaltham, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerDYN
- Price$13.91-1.00%
Trading Information
- Market cap$1.42B
- Float75.29%
- Average Daily Volume (1m)2,439,383
- Average Daily Volume (3m)1,692,620
- EPS-$3.56
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$97.13M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$105.26M
- EV$2.92B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B2.01
- Debt/Equity3.52
Documents
Add to research
SEC Filings
Factset Street Account
Factset